NDAINTRAVENOUSSOLUTION
Approved
Oct 2024
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
6/8 — Strong
BEIZRAY (docetaxel) by Sanofi is functions. Approved for breast cancer, non-small cell lung cancer. First approved in 2024.
Drug data last refreshed 19h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BEIZRAY (docetaxel) is a microtubule-stabilizing chemotherapy agent approved by the FDA on October 23, 2024, for breast cancer and non-small cell lung cancer. The drug works by binding to free tubulin, promoting stable microtubule assembly while inhibiting disassembly, ultimately blocking cell division. It is administered as an intravenous solution.
Growth10.0 years to LOE
Early-stage product in growth phase with potential for team expansion as commercial infrastructure is built post-approval.
Mechanism of Action
functions. Docetaxel binds to free tubulin and promotes the assembly of tubulin into stable microtubules while simultaneously inhibiting their disassembly. This leads to the production of microtubule bundles without normal function and to the stabilization of microtubules, which results in the…
Pharmacologic Class:
Microtubule Inhibitor
Indications (2)
Worked on BEIZRAY at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.